Prostate cancer is the second most common cancer in American men. While the disease is prevalent across the country, the screening guidelines are not. Prostate cancer screenings have always been somewhat controversial because the tests often alert physicians to the presence of cancer, but there is no precise way to determine, definitively, whether the cancer […]
As the COVID-19 pandemic continues, many cancer patients are having to make the difficult decision to continue with their current cancer regimen or delay treatments. Cancer patients and physicians must carefully weigh the potential benefit of routine cancer care versus the risk of COVID-19. To help ease these decisions, several peer-reviewed, non-profit cancer care organizations […]
Two clinical trials opened for enrollment in late 2019 at UofL Health – James Graham Brown Cancer Center for eligible men with prostate cancer. “Since the Brown Cancer Center has these clinical trials available, we can offer our prostate cancer patients the latest cancer treatments,” Scott Silva, M.D., Ph.D. , radiation oncologist, said. Men with favorable intermediate risk […]
When deciding which treatment option is best for their prostate cancer, men take numerous factors into consideration. While their physician’s recommendation does play an important role in the treatment decision, in the end, most men make the choice that is best for them. That choice is often based on treatment outcomes and side effects, and […]
Accuray Incorporated, developer and manufacturer of the CyberKnife® System, announced that published data from two multicenter studies using differing protocols provide consistent results and reinforce the use of the CyberKnife system for the effective management of low-and intermediate-risk prostate cancer. The studies are the largest conducted to date evaluating stereotactic body radiation therapy (SBRT) in […]
Last week, the American Urological Association (AUA), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) released collaborative clinical guidelines for managing localized prostate cancer which offers a framework for shared decision-making between physicians and patients. Through this collaboration, the committee provided guidance on active surveillance and on which treatments […]
The U.S. Preventive Services Task Force (USPSTF) recently updated their prostate screening recommendations. On April 11, 2017, the USPSTF issued an updated draft recommendation on screening for prostate cancer. The updated recommendation changes the grade for PSA-based screening from “D” to “C” for men 55 – 69 years of age. As a result, the USPSTF […]
A recent research paper in Oncotarget, a weekly peer-reviewed open access medical journal covering research on all aspects of oncology, reported that researchers from UR Medicine’s Wilmot Cancer Institute and Roswell Park Cancer Institute have discovered a possible new tool for predicting whether prostate cancer will reoccur following surgery based on the expression patterns of […]
June is National Cancer Survivor Month. It is a month dedicated to celebrating and recognizing those who have survived cancer, an inspiration for those recently diagnosed, a gathering of support for families, and an outreach to the community. According to the Centers for Disease Control and Prevention (CDC), the leading national public health institute […]
